Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil

Neurology

Volumn 72, Issue 4, 2009, Pages 337-340

  Moravan, Michael ^a   Segal, Benjamin M ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GADOLINIUM; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COORDINATION DISORDER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SARCOIDOSIS; SEIZURE; SENSORY DYSFUNCTION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CENTRAL NERVOUS SYSTEM DISEASE; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 60549111956     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000341278.26993.22     Document Type: Article

References (10)

1. Ferriby D, de Seze J, Stojkovic T, et al. Long-term follow-up of neurosarcoidosis. Neurology 2001;57:927-929.
2. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis: diagnosis and management. QJM 1999;92:103-117.
3. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42.
4. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-740.
5. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004;64:1767-1777.
6. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004;63:318-320.
7. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004;117:277-279.
8. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002;59:1660-1661.
9. Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004;251:760-761.
10. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-1888.